In recent years, molecular targeted drugs involved in the pathogenesis and progression of cancer are being extensively investigated. Anlotinib, a novel multi-target tyrosine kinase inhibitor, is the first third-line treatment approved for patients with advanced non-small cell lung cancer in China, and has been approved for the treatment of soft tissue sarcoma, small cell lung cancer, medullary thyroid cancer and differentiated thyroid cancer. Numerous studies in China and abroad have found that this drug has three major functions, which are anti-tumor angiogenesis, inhibition of tumor growth and remodelling of the tumor microenvironment, and it can inhibit the development of solid tumours through various mechanisms. In this review, we summarize the role of anlotinib in various malignancies and research progress of related mechanism, to provide reference for its clinical application in oncology treatment.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |